Search - tctmd.com

Displaying 561 - 580 of 689

Sort: Relevancy | Date

Presentation TCT 2016

How to Be a Key Investigator? Its Not Just Quantity- Quality Is Top Priority

Presenter: David A. Cox, Thomas D. Stuckey

October 30, 2016

Presentation TCT 2016

Medical Management of Non-Obstructive HCM: When and Which Medications?

Presenter: Bernard J. Gersh, Harry Rakowski, John S. Douglas Jr

October 30, 2016

Presentation TCT 2016

Quality and Compliance in Research: The Crucial First Step

Presenter: David A. Cox, Thomas D. Stuckey, Kate Dalton

October 30, 2016

Presentation TCT 2016

Building a Successful Clinical Research Enterprise at Your Hospital: Integrating Clinical Work Flow and Research

Presenter: David A. Cox, Thomas D. Stuckey, Tamim Nazif

October 30, 2016

Presentation TCT 2016

Genetic Testing in Hypertrophic Cardiomyopathy: Role in Prognostication and Screening

Presenter: Howard C. Herrmann, Sherif F. Nagueh, Robert Roberts

October 30, 2016

Presentation TCT 2016

Cardiac Catheterization Is Essential for Hemodynamic Assessment

Presenter: Howard C. Herrmann, Sherif F. Nagueh

October 30, 2016

Presentation TCT 2016

Cardiac MR for Diagnosis and Guiding Management of HCM

Presenter: Howard C. Herrmann, Sherif F. Nagueh, Andrew E. Arai

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Poor Femoral Access

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Richard Smalling

October 30, 2016

Presentation TCT 2016

Echocardiography Essentials for Comprehensive Evaluation of HCM

Presenter: Howard C. Herrmann, Sherif F. Nagueh

October 30, 2016

Presentation TCT 2016

Severe AS and Extreme Co-morbidities (Futile Patient?)

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Suzanne V. Arnold

October 30, 2016

Presentation TCT 2016

Management of Failing Aortic Bioprosthesis

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Danny Dvir

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Atrial Fibrillation

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach

October 30, 2016

Presentation TCT 2016

My Rosy Prophecy: What Will the Specialty of Mitral Valve Therapeutics Look Like in 10 Years?

Presenter: James S. Gammie, James B. Hermiller Jr., Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Surgical Mitral Valve Repair Or Replacement Via A Minimally Invasive Approach Will Be The Gold Standard!

Presenter: James S. Gammie, James B. Hermiller Jr., Steven F. Bolling

October 30, 2016

Presentation TCT 2016

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? No, The Bar Is Too High Transcatheter Mitral Repair Will Always Be Safer And Nearly As Effective!

Presenter: James S. Gammie, James B. Hermiller Jr., Ted Feldman

October 30, 2016

Presentation TCT 2016

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Transcatheter MV Replacement Will Become Standard Of Care For Secondary MR!

Presenter: James S. Gammie, James B. Hermiller Jr., Stephan Windecker

October 30, 2016

Presentation TCT 2016

First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care!

Presenter: James S. Gammie, James B. Hermiller Jr., Alfredo Trento

October 30, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team!

Presenter: James S. Gammie, James B. Hermiller Jr., Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Advertisement

How to Be a Key Investigator? Its Not Just Quantity- Quality Is Top Priority

Medical Management of Non-Obstructive HCM: When and Which Medications?

Quality and Compliance in Research: The Crucial First Step

Building a Successful Clinical Research Enterprise at Your Hospital: Integrating Clinical Work Flow and Research

Genetic Testing in Hypertrophic Cardiomyopathy: Role in Prognostication and Screening

Cardiac Catheterization Is Essential for Hemodynamic Assessment

Cardiac MR for Diagnosis and Guiding Management of HCM

TAVR in Patients With Poor Femoral Access

Echocardiography Essentials for Comprehensive Evaluation of HCM

Severe AS and Extreme Co-morbidities (Futile Patient?)

Management of Failing Aortic Bioprosthesis

TAVR in Patients With Atrial Fibrillation

My Rosy Prophecy: What Will the Specialty of Mitral Valve Therapeutics Look Like in 10 Years?

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Surgical Mitral Valve Repair Or Replacement Via A Minimally Invasive Approach Will Be The Gold Standard!

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? No, The Bar Is Too High Transcatheter Mitral Repair Will Always Be Safer And Nearly As Effective!

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Transcatheter MV Replacement Will Become Standard Of Care For Secondary MR!

First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care!

Personalized Medicine Where Are We in 2016?

First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team!

Anti-inflammatory Therapies for Atherosclerosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content